The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Immune Thrombocytopenia Treatment-Global Market Insights and Sales Trends 2024
Synopsis
Immune thrombocytopenia (ITP) is a bleeding disorder caused by thrombocytopenia not associated with a systemic disease. Typically, it is chronic in adults, but it is usually acute and self-limited in children. Spleen size is normal in the absence of another underlying condition.
The global Immune Thrombocytopenia Treatment market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Immune Thrombocytopenia Treatment in various end use industries. The expanding demands from the Hospitals and Clinics, Research and Academic Institutes and Others,, are propelling Immune Thrombocytopenia Treatment market. Corticosteroids, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Intravenous Immunoglobulin (IVIG) segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Immune Thrombocytopenia Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Immune Thrombocytopenia Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Immune Thrombocytopenia Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Immune Thrombocytopenia Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Immune Thrombocytopenia Treatment covered in this report include CSL Behring, Amgen, F.Hoffmann-La Roche, Kyowa Hakko Kirin, Rigel Pharmaceuticals, Shionogi, Dova Pharmaceuticals, Novartis and Shire, etc.
The global Immune Thrombocytopenia Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
CSL Behring
Amgen
F.Hoffmann-La Roche
Kyowa Hakko Kirin
Rigel Pharmaceuticals
Shionogi
Dova Pharmaceuticals
Novartis
Shire
Ligand Pharmaceuticals
GSK
Grifols Biologicals
Jiangsu Hengrui Pharmaceutical
Global Immune Thrombocytopenia Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Immune Thrombocytopenia Treatment market, Segment by Type:
Corticosteroids
Intravenous Immunoglobulin (IVIG)
Anti-D Immunoglobulin
Thrombopoietin Receptor Agonist (TPO-RA)
Others
Global Immune Thrombocytopenia Treatment market, by Application
Hospitals and Clinics
Research and Academic Institutes
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Immune Thrombocytopenia Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Immune thrombocytopenia (ITP) is a bleeding disorder caused by thrombocytopenia not associated with a systemic disease. Typically, it is chronic in adults, but it is usually acute and self-limited in children. Spleen size is normal in the absence of another underlying condition.
The global Immune Thrombocytopenia Treatment market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Immune Thrombocytopenia Treatment in various end use industries. The expanding demands from the Hospitals and Clinics, Research and Academic Institutes and Others,, are propelling Immune Thrombocytopenia Treatment market. Corticosteroids, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Intravenous Immunoglobulin (IVIG) segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Immune Thrombocytopenia Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Immune Thrombocytopenia Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Immune Thrombocytopenia Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Immune Thrombocytopenia Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Immune Thrombocytopenia Treatment covered in this report include CSL Behring, Amgen, F.Hoffmann-La Roche, Kyowa Hakko Kirin, Rigel Pharmaceuticals, Shionogi, Dova Pharmaceuticals, Novartis and Shire, etc.
The global Immune Thrombocytopenia Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
CSL Behring
Amgen
F.Hoffmann-La Roche
Kyowa Hakko Kirin
Rigel Pharmaceuticals
Shionogi
Dova Pharmaceuticals
Novartis
Shire
Ligand Pharmaceuticals
GSK
Grifols Biologicals
Jiangsu Hengrui Pharmaceutical
Global Immune Thrombocytopenia Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Immune Thrombocytopenia Treatment market, Segment by Type:
Corticosteroids
Intravenous Immunoglobulin (IVIG)
Anti-D Immunoglobulin
Thrombopoietin Receptor Agonist (TPO-RA)
Others
Global Immune Thrombocytopenia Treatment market, by Application
Hospitals and Clinics
Research and Academic Institutes
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Immune Thrombocytopenia Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Immune Thrombocytopenia Treatment
1.1 Immune Thrombocytopenia Treatment Market Overview
1.1.1 Immune Thrombocytopenia Treatment Product Scope
1.1.2 Immune Thrombocytopenia Treatment Market Status and Outlook
1.2 Global Immune Thrombocytopenia Treatment Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Immune Thrombocytopenia Treatment Market Size by Region (2018-2029)
1.4 Global Immune Thrombocytopenia Treatment Historic Market Size by Region (2018-2023)
1.5 Global Immune Thrombocytopenia Treatment Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Immune Thrombocytopenia Treatment Market Size (2018-2029)
1.6.1 North America Immune Thrombocytopenia Treatment Market Size (2018-2029)
1.6.2 Europe Immune Thrombocytopenia Treatment Market Size (2018-2029)
1.6.3 Asia-Pacific Immune Thrombocytopenia Treatment Market Size (2018-2029)
1.6.4 Latin America Immune Thrombocytopenia Treatment Market Size (2018-2029)
1.6.5 Middle East & Africa Immune Thrombocytopenia Treatment Market Size (2018-2029)
2 Immune Thrombocytopenia Treatment Market by Type
2.1 Introduction
2.1.1 Corticosteroids
2.1.2 Intravenous Immunoglobulin (IVIG)
2.1.3 Anti-D Immunoglobulin
2.1.4 Thrombopoietin Receptor Agonist (TPO-RA)
2.1.5 Others
2.2 Global Immune Thrombocytopenia Treatment Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Immune Thrombocytopenia Treatment Historic Market Size by Type (2018-2023)
2.2.2 Global Immune Thrombocytopenia Treatment Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Immune Thrombocytopenia Treatment Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Immune Thrombocytopenia Treatment Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Immune Thrombocytopenia Treatment Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Immune Thrombocytopenia Treatment Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Immune Thrombocytopenia Treatment Revenue Breakdown by Type (2018-2029)
3 Immune Thrombocytopenia Treatment Market Overview by Application
3.1 Introduction
3.1.1 Hospitals and Clinics
3.1.2 Research and Academic Institutes
3.1.3 Others
3.2 Global Immune Thrombocytopenia Treatment Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Immune Thrombocytopenia Treatment Historic Market Size by Application (2018-2023)
3.2.2 Global Immune Thrombocytopenia Treatment Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Immune Thrombocytopenia Treatment Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Immune Thrombocytopenia Treatment Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Immune Thrombocytopenia Treatment Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Immune Thrombocytopenia Treatment Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Immune Thrombocytopenia Treatment Revenue Breakdown by Application (2018-2029)
4 Immune Thrombocytopenia Treatment Competition Analysis by Players
4.1 Global Immune Thrombocytopenia Treatment Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Immune Thrombocytopenia Treatment as of 2022)
4.3 Date of Key Players Enter into Immune Thrombocytopenia Treatment Market
4.4 Global Top Players Immune Thrombocytopenia Treatment Headquarters and Area Served
4.5 Key Players Immune Thrombocytopenia Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Immune Thrombocytopenia Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 CSL Behring
5.1.1 CSL Behring Profile
5.1.2 CSL Behring Main Business
5.1.3 CSL Behring Immune Thrombocytopenia Treatment Products, Services and Solutions
5.1.4 CSL Behring Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2018-2023)
5.1.5 CSL Behring Recent Developments
5.2 Amgen
5.2.1 Amgen Profile
5.2.2 Amgen Main Business
5.2.3 Amgen Immune Thrombocytopenia Treatment Products, Services and Solutions
5.2.4 Amgen Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2018-2023)
5.2.5 Amgen Recent Developments
5.3 F.Hoffmann-La Roche
5.3.1 F.Hoffmann-La Roche Profile
5.3.2 F.Hoffmann-La Roche Main Business
5.3.3 F.Hoffmann-La Roche Immune Thrombocytopenia Treatment Products, Services and Solutions
5.3.4 F.Hoffmann-La Roche Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2018-2023)
5.3.5 Kyowa Hakko Kirin Recent Developments
5.4 Kyowa Hakko Kirin
5.4.1 Kyowa Hakko Kirin Profile
5.4.2 Kyowa Hakko Kirin Main Business
5.4.3 Kyowa Hakko Kirin Immune Thrombocytopenia Treatment Products, Services and Solutions
5.4.4 Kyowa Hakko Kirin Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2018-2023)
5.4.5 Kyowa Hakko Kirin Recent Developments
5.5 Rigel Pharmaceuticals
5.5.1 Rigel Pharmaceuticals Profile
5.5.2 Rigel Pharmaceuticals Main Business
5.5.3 Rigel Pharmaceuticals Immune Thrombocytopenia Treatment Products, Services and Solutions
5.5.4 Rigel Pharmaceuticals Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2018-2023)
5.5.5 Rigel Pharmaceuticals Recent Developments
5.6 Shionogi
5.6.1 Shionogi Profile
5.6.2 Shionogi Main Business
5.6.3 Shionogi Immune Thrombocytopenia Treatment Products, Services and Solutions
5.6.4 Shionogi Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2018-2023)
5.6.5 Shionogi Recent Developments
5.7 Dova Pharmaceuticals
5.7.1 Dova Pharmaceuticals Profile
5.7.2 Dova Pharmaceuticals Main Business
5.7.3 Dova Pharmaceuticals Immune Thrombocytopenia Treatment Products, Services and Solutions
5.7.4 Dova Pharmaceuticals Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2018-2023)
5.7.5 Dova Pharmaceuticals Recent Developments
5.8 Novartis
5.8.1 Novartis Profile
5.8.2 Novartis Main Business
5.8.3 Novartis Immune Thrombocytopenia Treatment Products, Services and Solutions
5.8.4 Novartis Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2018-2023)
5.8.5 Novartis Recent Developments
5.9 Shire
5.9.1 Shire Profile
5.9.2 Shire Main Business
5.9.3 Shire Immune Thrombocytopenia Treatment Products, Services and Solutions
5.9.4 Shire Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2018-2023)
5.9.5 Shire Recent Developments
5.10 Ligand Pharmaceuticals
5.10.1 Ligand Pharmaceuticals Profile
5.10.2 Ligand Pharmaceuticals Main Business
5.10.3 Ligand Pharmaceuticals Immune Thrombocytopenia Treatment Products, Services and Solutions
5.10.4 Ligand Pharmaceuticals Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2018-2023)
5.10.5 Ligand Pharmaceuticals Recent Developments
5.11 GSK
5.11.1 GSK Profile
5.11.2 GSK Main Business
5.11.3 GSK Immune Thrombocytopenia Treatment Products, Services and Solutions
5.11.4 GSK Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2018-2023)
5.11.5 GSK Recent Developments
5.12 Grifols Biologicals
5.12.1 Grifols Biologicals Profile
5.12.2 Grifols Biologicals Main Business
5.12.3 Grifols Biologicals Immune Thrombocytopenia Treatment Products, Services and Solutions
5.12.4 Grifols Biologicals Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2018-2023)
5.12.5 Grifols Biologicals Recent Developments
5.13 Jiangsu Hengrui Pharmaceutical
5.13.1 Jiangsu Hengrui Pharmaceutical Profile
5.13.2 Jiangsu Hengrui Pharmaceutical Main Business
5.13.3 Jiangsu Hengrui Pharmaceutical Immune Thrombocytopenia Treatment Products, Services and Solutions
5.13.4 Jiangsu Hengrui Pharmaceutical Immune Thrombocytopenia Treatment Revenue (US$ Million) & (2018-2023)
5.13.5 Jiangsu Hengrui Pharmaceutical Recent Developments
6 North America
6.1 North America Immune Thrombocytopenia Treatment Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Immune Thrombocytopenia Treatment Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Immune Thrombocytopenia Treatment Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Immune Thrombocytopenia Treatment Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Immune Thrombocytopenia Treatment Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Immune Thrombocytopenia Treatment Market Dynamics
11.1 Immune Thrombocytopenia Treatment Industry Trends
11.2 Immune Thrombocytopenia Treatment Market Drivers
11.3 Immune Thrombocytopenia Treatment Market Challenges
11.4 Immune Thrombocytopenia Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
